Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cheers for the document from the middle of last year, SMTrading. Rightly or wrongly, the following Q&A in particular (prior to the arrival of this latest CEO) suggested to me an in-house mentality of "Sleepy Hollow" with a need for a shake-up. I was particularly taken by the statement, "(Social media are) not cost-effective methods of communication
based on the level of feedback we received." Erm, so that'll be why Twitter and the like has never taken off?! Business To Business Comms are fine but they are hardly likely to attract potential investors, the vast majority of which are not working in the field. I would again refer them to my previous suggestions.
Q. What has happened to the Company’s presence on social media platforms
such as Twitter?
A. We have previously explored the value of different social media platforms including
Twitter and LinkedIn but these were not cost-effective methods of communication
based on the level of feedback we received. Managing content is labour-intensive and
requires regular new material to maintain high rankings and we concluded that
resources would be better allocated to more immediate business-to-business
communications. We regularly review this within the Company and will look to allocate
resources to it when a compelling business case is identified."
This is the big news that everyone is waiting for we have two horses running in the race
Should read this it will explain better
https://www.proteomics.com/news/post/shareholder-questions-answers-agm-26-june-2020
I've messaged them too. I just hope they "get it" and don't exist under the sole illusion of the "we're scientists" banner. In that case or if they are uncomfortable with the limelight then bring in someone to fulfill what is a key role.
Exactly! Hope they read yr post ! .. what are they doing to improve shareholder value ? It’s like
They r in their own bubble with no intention to grow just bumble along getting some orders in.. mariola her role is to take and lead us , but no communication since her coming . I need to see dynamism and vision, but clearly proteome
U need to be effective in COMMUNICATION.
I agree with your last comment, AngelMarbles. Whilst understanding this is a relatively small company, the website looks like something you'd create if producing your own blog from home. I do appreciate that somebody probably gives up their valuable time to update the site and on a limited budget. However, the company needs to do much better on the PR front, website included and especially online via the likes of social media and Youtube where they, a self-professed as "Leader in Applied Proteomics and Peptidomics" currently have virtually no presence whatsoever. The main offerings seem to come via the occasional RNS or through pointing us in the direction of secondary articles from other published sources. What do I look for from a company in a dynamic industry on the PR front?
1) A website that includes fairly regular, interesting and informative content and Presentations (Video and audio). Any movement from what we have at present would be helpful.
2) The same presentations posted to other digital platforms.
3) Interviews with the CEO when key news is announced with the likes of "Proactive Investors" and "Directors Talk".
4) Utilize Twitter, Facebook and Instagram to regularly remind prospective and current investors of your existence.
5) Take part in the various webinars available to them in order to publicise the company.
This may sound like a lot of work but it doesn't need to be once the workflow and some decent contacts have been put in place with some money spent. I'm not even sure if this company has a PR firm? Either way, they'll need to improve under the new CEO if she is serious about bringing "shareholder value". I wish her well.
Jeff bezos sees the value with nautilus proteomics company .. all these elites getting into the things that will transform Society.
..https://www.google.co.uk/amp/s/www.geekwire.com/2021/jeff-bezos-backed-startup-nautilus-biotechnology-set-go-public-via-spac-900m-valuation/amp/
Come on proteome sciences update your website, it looks tired and old , and get some wind in your sails ! We are on the cusp of a biotech revolution in proteomics , so advise the market .
Been watching foods like honey and cannabis foods .. there are so many things that need testing to find their origins and potency levels , and find contaminants .. for instance honey there is much adulterated honey on the market from China and these foods need testing .. they are using these testing Pcr machine to analysis .. can u see the market is huge? Or am I the only one ?
:) it’s good to see rises. As we have been stuck in the 3 level .. but it seems proteomics is the new thing now for biotechs and we are getting lots of updates .. it’s actually for every sort of biotech trying to come up with therapies for the disease and analysis , even fats and health , weight loss .. can u imagine the market there .. then individualised health plans as we look are our genetic proteome interplay
A nice spot to make a home for a while. Nobody likes a home that's too noisy anyway
Hi geom .. lol .. yes a few more to liven this bb .. welcome. . As u can see ive been lonely for some time here .. lol
AI. & proteomics
https://analyticsindiamag.com/how-artificial-intelligence-is-reviving-proteomics/
WHAT A TREAT
I'll help you out on this one. Not too knotted :-)
January 26, 2021 Calico Life Sciences LLC and Thermo Fisher Scientific have published a paper for the automation of 16-Plex Plasma Proteomics with Real-Time Search and Ion Mobility Mass Spectrometry. Abstract Performing large-scale plasma proteome profiling is challenging due to limitations imposed by lengthy preparation and instrument time. We present a fully automated multiplexed proteome profiling platform (AutoMP3) using the Hamilton Vantage liquid handling robot capable of preparing hundreds to thousands of samples. To maximize protein depth in single-shot runs, we combined 16-plex Tandem Mass Tags (TMTpro) with high-field asymmetric waveform ion mobility spectrometry (FAIMS Pro) and real-time search (RTS). We quantified over 40 proteins/min/sample, doubling the previously published rates. HTTPS://pubs.acs.org/doi/10.1021/acs.jproteome.0c00681 HTTPS://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.0c00681 HTTPS://www.calicolabs.com/
I Were a big biotech or a chemistry medical computer or nueroscience company that is now linking digital chemistry and biology I’d be looking to acquire proteome sciences; for a biotech drug developer they would do all their in-house work to fast track their drug development/medical research . Also oxfordbiodyn the bigger proteomics company (the other diggle brother investor) has a new senior tech computer engineer to promote their platform ..
Proteome sciences looks to be a bargain if it can up its game / ripe for takeover
Rns was great but we need more regular communication proteome sciences ; slowly slowly more investors are investing .
Nice post Jones .. it is the proteome that is the key to understanding disease and how it interacts in the body .. mass spectrometry equipment is on the rise , and we have a top notch one in tmtpro .. it can test more variables .. I have before talked about how I can see potential with proteomics and digital chemistry applications , like deepmatter .
Proteomics Could Be the Next ‘Omics Frontier
Simon-Barnett By Simon Barnett | @sbarnettARK
Analyst
The ‘omics revolution describes how technology is transforming our understanding of the fundamental building blocks of life. Starting with the Human Genome Project more than 20 years ago, next-generation DNA sequencing accelerated the genomics revolution. Thanks to recent research breakthroughs, next generation sequencing (NGS) instruments can study the transcriptome—the collection of RNA molecules in an organism. The natural next step for the ‘omics revolution, in our view, is proteomics—the analysis of proteins.
Proteomics involves the study of the three-dimensional structure and sequence of protein molecules. Improvements in mass-spectrometry and novel techniques like Cryo-EM are helping researchers identify the structure of proteins. A few weeks ago, Google’s DeepMind shocked the world with AlphaFold (v2), a neural-network-based algorithm capable of converting a protein sequence into an accurate structural prediction.
Absent still is the ability to develop high-throughput, high-accuracy next-generation protein sequencing (NGPS). In our view, NGPS is lagging behind NGS because of several engineering obstacles. Among them are:
The proteome could have 1,000,000 unique molecules while the transcriptome has 100,000 and the genome 20,000 (genes).
The proteome is changing constantly inside our bodies, both tissue-to-tissue and time-to-time, while the genome is fairly conserved.
Proteins include 20 unique molecules (amino acids) while DNA and RNA have four (4) bases.
Proteins often are less thermodynamically stable than RNA and DNA.
Nature has evolved natural enzymes, such as polymerases, that assist in DNA and RNA sequencing. Proteins do not have the same luxury.
Life sciences entrepreneur, Jonathan Rothberg, is exploring this new frontier. His company, Quantum SI (private), recently filed a patent that describes NGPS methods and compositions addressing many of these challenges. In our view, an instrument capable of sequencing proteins with single-molecule accuracy and high sample throughput - cost-effectively - could turbocharge the ‘omics revolution.
Hello newbies. Please post more often ! :-). Good results and onwards and upwards
Results look very good to me. Profit up, cash in bank up, positive order book, marginal cost increase and all looks rosy........Buy more???
A POSITIVE RNS AND RESULTS FROM THE CHIEF EXECUTIVE Dr. Mariola Soehngen.
"The Company made good progress in 2020 and we were able to deliver results in line with the indications outlined in our H1 2020 report. The improved cash position at the end of 2020 provides a good platform for the new year and the substantial order book value we are carrying forward puts our service business in a strong position for 2021. We expect that the traction we are seeing on key partnerships developed in 2020 will continue.
Finally I would like to stress that I joined the company in September 2020 convinced that there is excellent potential in our business and markets. Proteomics is increasingly being regarded an integral part of research and development projects, so we expect the demand to increase further. I am excited to be on board, very pleased with the capability of the business and our people and convinced we have a bright future. We have begun a re-evaluation of our strategy and will evaluate both organic and external opportunities. I look forward to interacting with our shareholders and all other stakeholders and am convinced of the opportunity to create value for all constituents.
Great news to have cash in the bank and receive such positive comments from the Chief. I look forward to the Chief Executive's next update.
A good start to the week. GLA